Brief: U.S. FDA Approves Alk's Odactra® (House Dust Mite Allergen Extract) Tablet For Sublingual Use As Immunotherapy For Adolescents

Alk-Abello A/S

25/01/2023 13:19

Jan 25 (Reuters) - ALK-Abello A/S  ALKb.CO :
    * U.S. FDA APPROVES ALK'S ODACTRA® (HOUSE DUST MITE ALLERGEN
EXTRACT) TABLET FOR SUBLINGUAL USE AS IMMUNOTHERAPY FOR
ADOLESCENTS
    * ALK-ABELLO A/S - ODACTRA IS NOW INDICATED TO TREAT
HDM-INDUCED
ALLERGIC RHINITIS, WITH OR WITHOUT CONJUNCTIVITIS, IN PERSONS 12
TO 17 YEARS OF AGE

Source text for Eikon:  ID:nPn8P44Pxa 
Further company coverage:  ALKb.CO 
 ((Reuters.Briefs@thomsonreuters.com;;))